<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-143403" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Solitary Fibrous Tumors</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Abodunrin</surname>
            <given-names>Faith O.</given-names>
          </name>
          <aff>Creighton University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Killeen</surname>
            <given-names>Robert B.</given-names>
          </name>
          <aff>University of Illinois</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Faith Abodunrin declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Robert Killeen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>5</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-143403.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Solitary fibrous tumors (SFTs) represent a rare type of mesenchymal neoplasm that can arise in various locations throughout the body, although most commonly occur in the thoracic cavity. Despite typically exhibiting a benign clinical course, a subset of SFTs may demonstrate malignant behavior, leading to local recurrence and distant metastasis. Diagnosis often requires a multidisciplinary approach involving clinical, histological, immunohistochemical, and molecular assessments to differentiate SFTs from other soft tissue tumors. Treatment typically involves surgical resection, although adjuvant therapies such as radiation and chemotherapy may be considered in cases of unresectable or metastatic disease. Long-term follow-up is essential due to the potential for late recurrences and metastases, underscoring the importance of continued surveillance in managing patients with SFTs.</p>
        <p>Participating in this course offers clinicians a comprehensive understanding of SFTs, including their epidemiology, pathogenesis, clinical presentation, diagnostic modalities, and treatment strategies. Participants can expect to gain insight into the latest advancements in SFT management, including emerging therapeutic approaches and prognostic factors. Additionally,&#x000a0;they enhance their diagnostic skills by interpreting imaging studies, histopathological specimens, and molecular analyses, ultimately improving their ability to provide optimal care for patients with SFTs. Furthermore, the course highlights the importance of a multidisciplinary approach in managing SFTs, fostering collaboration among healthcare professionals to optimize patient outcomes and quality of life.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the characteristic clinical features and imaging findings associated with solitary fibrous tumors to facilitate prompt recognition and diagnosis.</p></list-item><list-item><p>Differentiate between solitary fibrous tumors and other soft tissue neoplasms based on histopathological examination and immunohistochemical staining patterns.</p></list-item><list-item><p>Implement evidence-based treatment strategies for solitary fibrous tumors, including surgical resection, radiation therapy, and systemic therapies, based on disease characteristics and patient preferences.</p></list-item><list-item><p>Collaborate with interprofessional teams to coordinate comprehensive care plans for patients with solitary fibrous tumors, addressing both medical and psychosocial needs.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=143403&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=143403">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-143403.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The historical evolution of solitary fibrous tumors (SFTs) traces back to the early 20th century when Klemperer and Rabin described their morphological features in pleural neoplasms in 1931.<xref ref-type="bibr" rid="article-143403.r1">[1]</xref><xref ref-type="bibr" rid="article-143403.r2">[2]</xref> Initially labeled as "solitary (localized) mesothelioma of pleura" by Stout and Murray in 1942, these tumors were later renamed "solitary fibrous tumor" by Stout and Hamidi in 1951. Concurrently, Stout and Murray introduced the term "hemangiopericytoma" (HPC) while studying a series of cases in 1942, refining diagnostic criteria and malignancy assessment features in subsequent studies. Although initially predominantly reported in the pleura and lungs until 1990, the recognition of extrathoracic SFTs expanded with the publication of the first series in 1991.<xref ref-type="bibr" rid="article-143403.r3">[3]</xref>&#x000a0;</p>
        <p>SFTs represent a diverse group of fibrotic mesenchymal neoplasms that are rarely malignant and have low metastatic potential. They usually follow an indolent course with an asymptomatic presentation.<xref ref-type="bibr" rid="article-143403.r4">[4]</xref> Despite their rarity, comprising only 3.7% of visceral and soft tissue sarcomas, SFTs can manifest anywhere in the body, most commonly in the abdomen.<xref ref-type="bibr" rid="article-143403.r5">[5]</xref><xref ref-type="bibr" rid="article-143403.r6">[6]</xref> Variability in morphological features, including histologic variants and potential malignancy, complicates diagnosis, often mimicking other soft tissue neoplasms. The correct identification of SFT is crucial due to differences in management and prognosis compared to its malignant counterparts. While SFTs typically exhibit a distinct immunohistochemical profile, diagnosis can pose challenges. The emergence of NAB2-STAT6 gene fusion as a sensitive molecular marker and its surrogate STAT6 immunostaining enhances diagnostic accuracy. However, its specificity in distinguishing SFT from other soft tissue tumors warrants further investigation.</p>
      </sec>
      <sec id="article-143403.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>While the exact etiology of SFTs remains unclear, data supports these tumors arising from mesenchymal origin cells.<xref ref-type="bibr" rid="article-143403.r7">[7]</xref>&#x000a0;Research suggests that genetic alterations, particularly the recurrent fusion of the&#x000a0;<italic toggle="yes">NAB2&#x000a0;</italic>and&#x000a0;<italic toggle="yes">STAT6</italic>&#x000a0;genes located at chromosomal region 12q13, play a crucial role in their pathogenesis.<xref ref-type="bibr" rid="article-143403.r3">[3]</xref>&#x000a0;To date, no environmental factors have been identified that increase the risk of SFT;&#x000a0;other factors that may contribute to the development of SFTs include hormonal influences and potential genetic predispositions.<xref ref-type="bibr" rid="article-143403.r7">[7]</xref>&#x000a0;However, further research is needed to elucidate the precise mechanisms involved in their etiology.</p>
      </sec>
      <sec id="article-143403.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>SFTs have been reported at almost every anatomic site.<xref ref-type="bibr" rid="article-143403.r8">[8]</xref>&#x000a0;SFTs have an age-adjusted incidence rate of 0.61 and 0.37 per million persons per year for extra meningeal and meningeal cases, respectively; in other words, we can assume an age-adjusted yearly incidence of 1 new case per million people.<xref ref-type="bibr" rid="article-143403.r8">[8]</xref>&#x000a0;The pleura is the most common site, accounting for approximately 30% of cases. Pleural SFTs represent less than 5% of all pleural tumors, with an estimated incidence of 2.8 per 100,000 people.<xref ref-type="bibr" rid="article-143403.r9">[9]</xref>&#x000a0;Other frequently involved sites include meninges (27%), abdominal cavity (20%), trunk (10%), extremities (8%), and the head and neck (5%).&#x000a0;Intracranial SFTs constitute 2.5% of meningeal neoplasms and less than 1% of all intracranial tumors.<xref ref-type="bibr" rid="article-143403.r10">[10]</xref>&#x000a0;SFTs typically&#x000a0;occur in&#x000a0;adults between 20 and 70, with a peak incidence in the 5th and 6th decades.<xref ref-type="bibr" rid="article-143403.r7">[7]</xref>&#x000a0;These tumors are rare in children and adolescents.<xref ref-type="bibr" rid="article-143403.r3">[3]</xref>&#x000a0;Pleural SFTs present at a somewhat older age (mean&#x02009;=&#x02009;60.2&#x02009;years) compared to meningeal (mean&#x02009;=&#x02009;50.6&#x02009;years) and extrapleural SFTs (mean&#x02009;=&#x02009;50.3&#x02009;years).<xref ref-type="bibr" rid="article-143403.r3">[3]</xref>&#x000a0;They tend to occur equally in men and women.<xref ref-type="bibr" rid="article-143403.r2">[2]</xref><xref ref-type="bibr" rid="article-143403.r11">[11]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-143403.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathophysiology of SFTs remains incompletely understood, although research suggests they arise from mesenchymal cells. These tumors typically harbor a recurrent fusion of the<italic toggle="yes">&#x000a0;NAB2</italic>&#x000a0;and&#x000a0;<italic toggle="yes">STAT6</italic>&#x000a0;genes located at chromosomal region 12q13, considered a molecular hallmark.<xref ref-type="bibr" rid="article-143403.r3">[3]</xref>&#x000a0;This fusion gene results in aberrant activation of&#x000a0;<italic toggle="yes">STAT6</italic>&#x000a0;signaling pathways, contributing to tumor development and progression. However, the exact mechanisms underlying the initiation and growth of SFTs are not fully elucidated.&#x000a0;</p>
        <p>SFTs, while often considered benign, can exhibit malignant behavior in a subset of cases. The malignant potential of SFTs is typically associated with specific clinical and histological features. These include older age, larger tumor size, increased cellularity, elevated mitotic activity (&#x0003e;4/10 high-power fields or &#x0003e;2 mitoses/2 mm<sup>2</sup>), nuclear pleomorphism, tumor necrosis, and infiltrative borders.<xref ref-type="bibr" rid="article-143403.r12">[12]</xref>&#x000a0;Tumors with such features are known to recur and metastasize. Importantly, no particular tumor location or imaging characteristics except tumor size, patient, environmental, or dietary factors have been implicated in the occurrence or malignant behavior of SFTs thus far.<xref ref-type="bibr" rid="article-143403.r13">[13]</xref>&#x000a0;Tumors lacking malignant histological features initially may acquire them at recurrence or metastasis.<xref ref-type="bibr" rid="article-143403.r14">[14]</xref>&#x000a0;In extrapleural and extra meningeal tumors, hypercellularity, increased mitotic rate, and nuclear pleomorphism are associated with recurrence and reduced overall survival. Additionally, patient age, tumor size, mitotic rate, and necrosis predict the time to metastasis and tumor-related death.&#x000a0;</p>
        <p>SFTs commonly&#x000a0;metastasize through hematogenous dissemination, most frequently to the lungs,&#x000a0;followed by the intrabdominal organs.<xref ref-type="bibr" rid="article-143403.r15">[15]</xref>&#x000a0;Lymphatic spread is rare. Metastatic disease, mainly&#x000a0;spread to&#x000a0;the lungs, is often the primary cause of mortality associated with SFTs. Extrathoracic SFTs seem to have a higher propensity for metastasis than thoracic SFTs.<xref ref-type="bibr" rid="article-143403.r15">[15]</xref>&#x000a0;The 2020 World Health Organization (WHO) classification of soft-tissue tumors categorizes SFT as an intermediate tumor, acknowledging its potential for metastasis, albeit rarely. This classification underscores the importance of vigilant monitoring and comprehensive management strategies for patients diagnosed with SFT.</p>
        <p>Despite tumor size often being considered a negative prognostic factor, SFTs can grow large without exhibiting aggressive behavior. They also tend to manifest as well-defined masses, with primary pleural tumors often presenting silently compared to those at extrapleural sites.<xref ref-type="bibr" rid="article-143403.r8">[8]</xref>&#x000a0;Furthermore, TP53 immunohistochemical expression and TERT promoter mutations have been linked to recurrence and metastasis, while dedifferentiation and specific anatomical locations are associated with poor prognosis. Recent risk stratification models incorporate factors like patient age, mitotic rate, tumor size, and percentage of tumor necrosis to more accurately predict prognosis and guide clinical management.<xref ref-type="bibr" rid="article-143403.r8">[8]</xref>&#x000a0;Therefore, while most SFTs are benign, a subset demonstrates malignant potential, necessitating careful histological evaluation and risk stratification to inform clinical decision-making.</p>
        <p>Paraneoplastic syndromes, although rare in SFTs, can present significant clinical challenges.<xref ref-type="bibr" rid="article-143403.r16">[16]</xref><xref ref-type="bibr" rid="article-143403.r17">[17]</xref>&#x000a0;Hypertrophic osteoarthropathy (HOA), also called Pierre-Marie Bamberg syndrome, is observed in less than 10% of cases (usually pleural) and often manifests as finger clubbing, hypertrophic skin changes, arthralgia, and increased periosteal activity.<xref ref-type="bibr" rid="article-143403.r18">[18]</xref>&#x000a0;Clubbing may be asymptomatic or associated with pain, typically affecting distal phalanges. Diagnosis relies on the combination of clubbing and increased periosteal activity on x-ray, suggesting systemic vascularization alterations induced by overexpression of vascular endothelial growth factor and platelet-derived growth factor. HOA is distinct from another syndrome characterized by hypoglycemia known as&#x000a0;Doege-Potter syndrome, occurring in less than 5% of SFT cases and linked to overproduction of insulin-like growth factor II. The effects of these syndromes typically diminish once the causative tumor is surgically removed. These paraneoplastic syndromes show the diverse systemic effects of SFTs and the importance of thorough clinical evaluation in diagnosis and management.<xref ref-type="bibr" rid="article-143403.r8">[8]</xref></p>
      </sec>
      <sec id="article-143403.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The pathological diagnosis of SFT is confirmed based on histological characteristics and immunohistochemistry (IHC). Histologically, SFTs exhibit a spectrum of morphological features characterized by ovoid to spindled cells with patternless growth against a collagenous stroma.<xref ref-type="bibr" rid="article-143403.r3">[3]</xref><xref ref-type="bibr" rid="article-143403.r13">[13]</xref>&#x000a0;Notably, prominent "staghorn"-shaped blood vessels and medium-sized vessels with perivascular fibrosis are common features.<xref ref-type="bibr" rid="article-143403.r19">[19]</xref>&#x000a0;The background stroma may display focal or diffuse myxoid changes.</p>
        <p>Classic fibrous SFTs are paucicellular and feature spindle-shaped cells within a prominent fibrous stroma. Cellular SFTs, conversely, are more densely cellular, with perivascular fibrosis and gaping blood vessels&#x000a0;at the periphery. Markedly, cellular tumors resembling hemangiopericytomas consist of sheets of primitive-appearing rounded cells. Meningeal SFTs tend to be more cellular and display hemangiopericytoma-like morphology. Some SFT variants include the fat-forming variant, characterized by abundant mature adipocytes, and the giant cell-rich variant, featuring multinucleated stromal giant cells. Additionally, dedifferentiation can occur in SFTs, leading to an abrupt transition to low- or high-grade sarcoma, often with spindle cell or undifferentiated pleomorphic sarcoma components. Squamous and neuroendocrine differentiation may also be observed in rare cases of SFTs.<xref ref-type="bibr" rid="article-143403.r3">[3]</xref></p>
        <p>Features suggesting the malignant nature of the mass, as reported from various case series, are moderate to severe atypia, high cell density, mitotic activity with more than 4 mitoses per high-powered field, margin infiltration, tumor size 10 cm or larger, varying degrees of pleomorphism, hemorrhage, and necrosis.<xref ref-type="bibr" rid="article-143403.r13">[13]</xref><xref ref-type="bibr" rid="article-143403.r20">[20]</xref>&#x000a0;While these features are useful in predicting malignant potential,&#x000a0;SFTs often exhibit unpredictable histologic behaviors.<xref ref-type="bibr" rid="article-143403.r21">[21]</xref>&#x000a0;The tumor immunophenotype can be characterized by CD34 and smooth-muscle-actin positivity and by S100 protein, creatine kinase pool, and desmin negativity.<xref ref-type="bibr" rid="article-143403.r22">[22]</xref>&#x000a0;</p>
        <p>IHC markers play a crucial role in diagnosing SFTs.&#x000a0;CD34 and STAT6 strongly support the diagnosis of SFT, with CD99 and Bcl-2&#x000a0;also&#x000a0;commonly used.<xref ref-type="bibr" rid="article-143403.r3">[3]</xref><xref ref-type="bibr" rid="article-143403.r12">[12]</xref>&#x000a0;However, their utility is limited due to their expression in other neoplasms that mimic SFT histologically. Notably, CD34 expression is observed in&#x000a0;81% to 95%&#x000a0;of SFTs but is often lost in malignant and dedifferentiated tumors. CD99 (about 75%) and Bcl-2 (over 90%) are sensitive to SFTs but lack specificity.<xref ref-type="bibr" rid="article-143403.r23">[23]</xref></p>
        <p><italic toggle="yes">STAT6</italic>&#x000a0;IHC stain has emerged as a valuable surrogate marker for&#x000a0;<italic toggle="yes">NAB2-STAT6</italic>&#x000a0;gene fusion, exhibiting excellent sensitivity and specificity. Per previous IHC features, the new&#x000a0;5th edition of the WHO Central Nervous System (CNS) tumors classification reported that STFs show&#x000a0;<italic toggle="yes">NAB2</italic>&#x000a0;and&#x000a0;<italic toggle="yes">STAT6</italic>&#x000a0;gene fusion and&#x000a0;<italic toggle="yes">STAT6</italic>&#x000a0;overexpression.<xref ref-type="bibr" rid="article-143403.r24">[24]</xref>&#x000a0;However,&#x000a0;<italic toggle="yes">STAT6</italic>&#x000a0;expression can also occur in other soft tissue neoplasms, necessitating careful interpretation.</p>
        <p>Additionally, gene expression profiling studies have identified overexpression of the&#x000a0;<italic toggle="yes">GRIA2</italic>&#x000a0;gene and aberrant expression of GRIA2 protein in SFT, further aiding in diagnosis. Aldehyde dehydrogenase 1 has also shown promise as a marker for SFT, particularly in conjunction with&#x000a0;<italic toggle="yes">STAT6</italic>&#x000a0;expression. Other markers, such as cytokeratins and epithelial membrane antigens, may exhibit multifocal expression in some SFT cases, adding to the diagnostic complexity.<xref ref-type="bibr" rid="article-143403.r3">[3]</xref></p>
      </sec>
      <sec id="article-143403.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>When evaluating a patient suspected of having an SFT, a comprehensive history and physical examination are crucial to the diagnostic process. Clinically, presenting symptoms of SFTs are specific to their site of origin but broadly include pain, a palpable mass, and typically neurologic or vascular symptoms. Urinary retention and bowel obstruction may be the presenting symptoms in patients with tumors of the abdomen or pelvis.<xref ref-type="bibr" rid="article-143403.r6">[6]</xref>&#x000a0;Therefore, the history-taking should include inquiries about the patient's presenting symptoms, such as pain, swelling, or changes in bowel or bladder habits, which may suggest the presence of a mass.&#x000a0;The patient&#x000a0;should also be asked about symptoms of hypoglycemia and joint pain that could correlate to paraneoplastic syndrome.<xref ref-type="bibr" rid="article-143403.r6">[6]</xref> Any relevant medical history, including surgeries or radiation exposure, should be elicited.&#x000a0;</p>
        <p>During the physical examination, attention should be paid to the location of the suspected tumor and any associated findings. Palpation of the area may reveal a firm, non-tender mass, although this can vary depending on the size and location of the tumor. Other signs to look for include skin changes overlying the mass, such as erythema or ulceration, and any signs of neurovascular compromise if the tumor is in a critical anatomical location.&#x000a0;</p>
        <p>In addition to the local examination, a thorough systemic evaluation should be performed to assess for signs of metastatic disease or paraneoplastic syndromes associated with SFTs. This includes a comprehensive neurological examination, assessment of respiratory function, inspection of nails to look for clubbing, and evaluation for symptoms suggestive of endocrine dysfunction. Overall, a detailed history and physical examination are essential for identifying potential signs and symptoms associated with SFTs, guiding further diagnostic workup, and determining appropriate management strategies.</p>
      </sec>
      <sec id="article-143403.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>
<bold>Radiological Studies</bold>
</p>
        <p>Obtaining radiologic imaging is usually the first step in diagnosing these tumors. Imaging studies such as computed tomography (CT) scans or magnetic resonance imaging (MRI) are essential for localizing the tumor, assessing its size, extent, and potential involvement of adjacent structures, and&#x000a0;identifying locoregional and distant metastases.<xref ref-type="bibr" rid="article-143403.r6">[6]</xref>&#x000a0;At times, other imaging, such as&#x000a0;2-deoxy-2-[fluorine-18]fluoro-D-glucose positron emission testing integrated with&#x000a0;CT (18F-FDG PET/CT) and ultrasound (US), may be of some utility.</p>
        <p>
<bold>CT</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>CT is the preferred initial diagnostic method for identifying SFTs. On CT scans, SFTs exhibit notable vascularity, with approximately 65% of cases demonstrating avid contrast enhancement. Enhancement is most conspicuous in the arterial and early portal venous phases, with a contrast washout in the delayed phase. However, if fibrous elements are predominant, contrast enhancement also becomes marked in the delayed phases.<xref ref-type="bibr" rid="article-143403.r25">[25]</xref>&#x000a0;Interestingly, about 35% of cases show large collateral feeding vessels. Heterogeneity in enhancement is more common in aggressive SFTs than indolent ones, seen in 76.5% versus 40.0% of cases, respectively. SFTs typically demonstrate intermediate to high attenuation on unenhanced CT scans due to dense collagen fibers and a rich capillary network. Heterogeneous attenuation is observed in approximately 88% of cases. Regions of low attenuation on unenhanced scans, seen in up to 86% of cases, correspond to gross necrosis, hemorrhage, or cystic changes within the tumor. These radiological findings aid in assessing tumor aggressiveness and guiding treatment decisions.<xref ref-type="bibr" rid="article-143403.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>On CTs, intrabdominal and retroperitoneal SFTs typically appear as well-defined, predominantly hypervascular masses with varying degrees of cystic change and necrosis. SFTs are generally isodense to adjacent muscles on unenhanced images and typically demonstrate avid yet heterogeneous enhancement following intravenous contrast administration. In certain tumors, central areas that do not enhance or enhance less could indicate necrosis or cyst formation. Although rare, calcifications may appear in larger benign or malignant tumors.<xref ref-type="bibr" rid="article-143403.r26">[26]</xref><xref ref-type="bibr" rid="article-143403.r27">[27]</xref>&#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p>While no pathognomonic imaging characteristics are associated with SFTs of the pleura, they typically present as well-circumscribed, homogenous masses originating from the pleural surface, occasionally with lobulated features.<xref ref-type="bibr" rid="article-143403.r28">[28]</xref><xref ref-type="bibr" rid="article-143403.r29">[29]</xref>&#x000a0;Enhanced CT scans often show increased vascularity within the tumor, leading to enhancement. Areas of cystic or myxoid degeneration within the tumor may appear hypoattenuated on contrast-enhanced CT.<xref ref-type="bibr" rid="article-143403.r28">[28]</xref>&#x000a0;SFTs of the pleura commonly displace or invade surrounding structures and may exhibit changes in position or shape during respiration, particularly if pedunculated.<xref ref-type="bibr" rid="article-143403.r30">[30]</xref>&#x000a0;Associated pleural effusion may be observed on CT imaging.<xref ref-type="bibr" rid="article-143403.r31">[31]</xref><xref ref-type="bibr" rid="article-143403.r32">[32]</xref>&#x000a0;Certain radiographic features, such as large size, pleural effusion, and necrosis, indicate malignant SFTs of the pleura. In some cases, calcifications may also be identified on CT scans.<xref ref-type="bibr" rid="article-143403.r26">[26]</xref><xref ref-type="bibr" rid="article-143403.r27">[27]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>MRI</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>SFTs present a diverse appearance on MRI, characterized by a mixture of solid and cystic components. On T1-weighted images, the solid areas of SFTs typically appear isointense relative to skeletal muscle, reflecting their fibrous composition. However, there can be variability in signal intensity, with some solid areas appearing hypointense.<xref ref-type="bibr" rid="article-143403.r8">[8]</xref><xref ref-type="bibr" rid="article-143403.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>Similarly, on T2-weighted images, the solid components of SFTs exhibit variable signal intensity, ranging from isointense to hypointense relative to skeletal muscle. Cystic areas within the tumor typically appear hyperintense on T2-weighted sequences, reflecting their fluid-filled nature.<xref ref-type="bibr" rid="article-143403.r8">[8]</xref><xref ref-type="bibr" rid="article-143403.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>SFTs typically demonstrate strong enhancement upon contrast administration, consistent with their vascularity. This enhancement pattern is similar to that observed on CT imaging and aids in distinguishing SFTs from other soft tissue masses. MRI may also be useful in showing necrosis, hemorrhage, and cystic changes if present.<xref ref-type="bibr" rid="article-143403.r25">[25]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>18F-FDG PET/CT&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>There are few descriptions in the literature regarding the&#x000a0;18F-FDG PET/CT manifestations of SFT.&#x000a0;Results from&#x000a0;1 study&#x000a0;found that benign SFT exhibit low-grade activity and malignant SFT tend to be strongly hypermetabolic and homogeneous.<xref ref-type="bibr" rid="article-143403.r33">[33]</xref>&#x000a0;Another study of 17 patients with confirmed SFT didn't show&#x000a0;18F-FDG PET/CT&#x000a0;to be a determinant in distinguishing indolent SFT (the old-fashioned typical SFT) from aggressive SFT (the old-fashioned malignant SFT). Still, it did conclude&#x000a0;that&#x000a0;18F-FDG PET/CT may have a limited role in diagnosing malignant SFTP in suspected patients.<xref ref-type="bibr" rid="article-143403.r34">[34]</xref></p>
          </list-item>
          <list-item>
            <p>In cases where there is suspicion of metastasis or recurrence,&#x000a0;18F-FDG PET/CT scans can be valuable for detecting distant sites of disease involvement. Metastatic SFTs may demonstrate increased FDG uptake in affected lymph nodes, bones, or distant soft tissues, helping to guide treatment decisions and assess prognosis.</p>
          </list-item>
          <list-item>
            <p>Additionally,&#x000a0;18F-FDG PET/CT scans can help monitor treatment response in patients undergoing chemotherapy, radiation therapy, or targeted therapies for SFTs. Changes in FDG uptake over time can provide valuable information about the effectiveness of treatment and guide further management strategies.</p>
          </list-item>
        </list>
        <p>
<bold>Ultrasound</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>US can be used in specific instances of SFT based on its location. In a patient case report of a&#x000a0;breast SFT in a 73-year-old man with a 12-month history of a palpable breast mass, the only associated clinical symptom was bilateral gynecomastia. In this case, a US examination revealed an oval, well-circumscribed, and hypoechoic mass with hypervascularity.<xref ref-type="bibr" rid="article-143403.r13">[13]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Invasive Procedures</bold>
</p>
        <p>SFT may be suspected based on imaging and clinical features. However, a definitive diagnosis requires histologic confirmation.</p>
        <p>
<bold>Core-needle biopsy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>A pretreatment biopsy to diagnose and grade the mass is ideal. This biopsy should be performed by an individual experienced in soft tissue mass biopsy techniques.&#x000a0;Fine-needle aspiration biopsies rarely provide adequate tissue samples to make a diagnosis. Core biopsies may be sufficient to establish the diagnosis of SFT but are commonly limited in showing histologic features indicative of an aggressive tumor.&#x000a0;Repeat biopsy can be considered if the initial biopsy is inadequate or fails to make the diagnosis. Depending on location, radiologic guided biopsy may be helpful.<xref ref-type="bibr" rid="article-143403.r7">[7]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Open incisional or excisional biopsy</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Open incisional or excisional biopsy plays a crucial role in the definitive diagnosis and workup of SFTs. When imaging studies suggest the presence of a soft tissue mass consistent with SFT, biopsy is typically recommended to obtain tissue samples for histopathological examination and IHC analysis.</p>
          </list-item>
          <list-item>
            <p>Incisional biopsy involves the removal of a small portion of the tumor tissue for examination, while excisional biopsy involves the complete removal of the tumor. The choice between incisional and excisional biopsy depends on various factors, including the size and location of the tumor, its proximity to vital structures, and the suspicion of malignancy. Some examples from case reports include:
<list list-type="bullet"><list-item><p>A patient presented with a suspected SFT in the pancreas and underwent a total pancreatectomy. The diagnosis of SFT was confirmed.<xref ref-type="bibr" rid="article-143403.r12">[12]</xref></p></list-item><list-item><p>A patient presented with obstructive gastrointestinal symptoms, and imaging showed a left abdominal mass consistent with a soft tissue mass. Surgical exploration revealed a firm mass in the left abdominal region originating from the mesojejunum and enclosed by omental adhesions. Therefore, complete tumor resection and partial omentectomy were performed to ensure safe surgical margins. The diagnosis was confirmed as mesenteric SFT.<xref ref-type="bibr" rid="article-143403.r25">[25]</xref></p></list-item><list-item><p>A patient presented with a large soft tissue mass of the penis&#x000a0;and underwent en bloc excision of the mass with consent for possible total penectomy and perineal urethrostomy. The diagnosis was confirmed to be penile SFT.<xref ref-type="bibr" rid="article-143403.r35">[35]</xref></p></list-item><list-item><p>A&#x000a0;patient was found to have a retroperitoneal mass on imaging. The patient subsequently underwent successful radical resection of the retroperitoneal mass, right nephrectomy, right adrenalectomy, and partial hepatectomy. The subsequent diagnosis was retroperitoneal SFT.<xref ref-type="bibr" rid="article-143403.r6">[6]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Histopathology</bold>
</p>
        <p>The excised tissue sample is sent to a pathology laboratory for histopathological examination by a pathologist. This examination involves analyzing the tissue under a microscope to evaluate its cellular composition, architecture, and other features characteristic of SFTs. Histopathological examination confirms the diagnosis of SFT based on characteristic morphological features such as spindle-shaped cells, patternless growth, and branching "staghorn" blood vessels. IHC staining may also be performed to detect specific markers associated with SFTs, such as CD34, STAT6, and Bcl-2, in the absence of other markers like desmin, S100 protein, epithelial membrane antigen, and low molecular weight cytokeratins is characteristic of SFTs.<xref ref-type="bibr" rid="article-143403.r36">[36]</xref>&#x000a0;Molecular testing may also detect the characteristic&#x000a0;<italic toggle="yes">NAB2-STAT6&#x000a0;</italic>gene fusion, providing further diagnostic confirmation. In addition to confirming the diagnosis, histopathological examination may provide insights into the subtype and grade of the SFT, which can influence treatment decisions and prognosis.&#x000a0;In summary, the evaluation and workup of an SFT involves a multidisciplinary approach, including clinical assessment, imaging studies, biopsy for histopathological evaluation, and molecular testing to confirm the diagnosis and assess the extent of disease spread. This comprehensive approach is essential for guiding treatment decisions and optimizing patient outcomes.</p>
      </sec>
      <sec id="article-143403.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Due to their rarity and lack of randomized control trials, there is no global consensus on treating SFTs. At present, the most effective therapeutic modality for SFTs is surgical resection. The role of other treatment modalities in the management of SFTs is unclear. Some reports in the literature have demonstrated radiotherapy's effectiveness in controlling SFTs. Chemotherapeutic drugs and novel targeted drugs seem to exert some activity on SFTs.&#x000a0;However, a consensus has not been achieved concerning the effectiveness of radiotherapy and chemotherapy against SFTs. Close multidisciplinary collaboration is essential for optimal management and outcomes in patients with SFTs.<xref ref-type="bibr" rid="article-143403.r3">[3]</xref><xref ref-type="bibr" rid="article-143403.r8">[8]</xref><xref ref-type="bibr" rid="article-143403.r25">[25]</xref></p>
        <p>
<bold>Surgery</bold>
</p>
        <p>Surgical resection, ideally achieving an R0 resection, is the primary treatment modality for localized SFTs and in cases of oligometastatic disease. The approach to surgery varies depending on the location of the tumor:</p>
        <p><bold>Thoracic SFTs:&#x000a0;</bold>These tumors are commonly attached to the visceral pleura and are often pedunculated. Surgical resection typically involves excision of the pulmonary edge. Other procedures, such as isolated parietal pleural resection, chest wall resections, or pulmonary wedge resections, may be performed for SFTs arising from the parietal pleura or lungs.<xref ref-type="bibr" rid="article-143403.r20">[20]</xref><xref ref-type="bibr" rid="article-143403.r37">[37]</xref>&#x000a0;Video-assisted thoracic surgery is increasingly utilized, particularly for smaller tumors (&#x0003c;10 cm).<xref ref-type="bibr" rid="article-143403.r38">[38]</xref>&#x000a0;In cases of pedunculated thoracic SFTs, preoperative angiography may be performed to identify feeding vessels, facilitating preoperative embolization or thoracoscopic ligation of vessels. For sessile SFTs, embolization is effective in reducing intraoperative bleeding.<xref ref-type="bibr" rid="article-143403.r39">[39]</xref></p>
        <p><bold>Abdominal SFTs:&#x000a0;</bold>SFTs in the abdominal cavity are most commonly located in the retroperitoneal space,&#x000a0;with the pelvic area involved less frequently. Surgical resection aims to achieve wide excision while sparing adjacent organs unless they are encased, adherent, or invaded by the tumor.<xref ref-type="bibr" rid="article-143403.r8">[8]</xref>&#x000a0;En bloc or piecemeal resections are performed, with some studies suggesting no significant difference in prognosis between the&#x000a0;2 approaches.<xref ref-type="bibr" rid="article-143403.r40">[40]</xref></p>
        <p><bold>Meningeal SFTs:&#x000a0;</bold>These tumors are typically attached to the dura mater, with common locations including the tentorium cerebelli, frontal convexity, cerebellopontine angle, ventricles, falx cerebri, and posterior fossa. Complete surgical resection is associated with a better prognosis, although microscopical margins are challenging to define due to tumor fragmentation during resection. Meningeal SFTs may require adjuvant radiotherapy for better local control.</p>
        <p><bold>Extremity SFTs:&#x000a0;</bold>Surgical resection for SFTs of the extremities follows standard principles similar to other soft tissue sarcomas. The thigh is the most common site; tumors typically present as well-circumscribed masses related to fascial tissue.</p>
        <p>Notably, preoperative embolization should also be considered in all cases, given the highly vascular nature of SFTs. In&#x000a0;1 case report of retroperitoneal SFT, approximately 17 L of blood loss was reported during the successful resection, highlighting the potential advantage of mass embolization preoperatively.<xref ref-type="bibr" rid="article-143403.r6">[6]</xref></p>
        <p>
<bold>Radiation</bold>
</p>
        <p>No prospective data supports neoadjuvant or adjuvant radiotherapy after surgical resection. The role of adjuvant radiation therapy is local control, especially in tumors at high risk for recurrence.<xref ref-type="bibr" rid="article-143403.r6">[6]</xref>&#x000a0;Patients with tumors with high-risk histologic features and positive surgical margins are likely to benefit from adjuvant radiation therapy.<xref ref-type="bibr" rid="article-143403.r3">[3]</xref><xref ref-type="bibr" rid="article-143403.r41">[41]</xref>&#x000a0;In locally recurrent&#x000a0;SFTs&#x000a0;of the pleura, adjuvant radiation therapy may be employed after reresection. Adjuvant radiotherapy has&#x000a0;also&#x000a0;been recommended in meningeal SFT, and even though no prospective study has been addressed, retrospective analysis suggests a clear trend toward significantly better local control if radiation therapy is added in the adjuvant setting.<xref ref-type="bibr" rid="article-143403.r42">[42]</xref>&#x000a0;Neoadjuvant radiotherapy may have a role as upfront therapy in patients with tumors that are large&#x000a0;and difficult to resect. Radiation therapy can be offered for palliation in patients with metastatic disease.<xref ref-type="bibr" rid="article-143403.r43">[43]</xref>&#x000a0;Due to the lack&#x000a0;of data on the use of radiotherapy, a highly individualized treatment plan should be made by a multidisciplinary team.</p>
        <p>
<bold>Chemotherapy</bold>
</p>
        <p>Chemotherapy has traditionally been utilized in managing advanced or metastatic SFTs, although prospective evidence regarding its efficacy is limited. Clinical trials specifically addressing the role of chemotherapy in SFTs are lacking, leading to uncertainties regarding its optimal use. However, retrospective studies and preclinical research have provided insights into the potential activity of various cytotoxic agents in different subtypes of SFTs.</p>
        <p>Anthracycline-based regimens have been the most extensively studied chemotherapy approach in SFTs. Often combined with ifosfamide, these regimens have shown modest response rates (10.5%&#x02013;20%) and progression-free survival (PFS) ranging from 3 to 5 months. Patients with dedifferentiated SFTs (DD-SFT) have exhibited longer PFS with anthracycline-based regimens than those with malignant SFTs.<xref ref-type="bibr" rid="article-143403.r8">[8]</xref></p>
        <p>Other cytotoxic agents, such as dacarbazine (DTIC) and temozolomide, have demonstrated promising activity in preclinical and clinical studies. DTIC and doxorubicin have shown substantial activity, with response rates ranging from 38% to 50% and a median PFS exceeding 6 months. Temozolomide, often combined with bevacizumab, has also shown positive results in retrospective studies.<xref ref-type="bibr" rid="article-143403.r44">[44]</xref><xref ref-type="bibr" rid="article-143403.r45">[45]</xref>&#x000a0;Trabectedin, an approved drug for pretreated metastatic soft tissue sarcomas, has shown activity in SFTs, particularly in translocation-related sarcomas like SFTs. Preclinical studies in SFT patient-derived xenograft models have demonstrated activity, and retrospective clinical data have reported variable but notable PFS outcomes.<xref ref-type="bibr" rid="article-143403.r44">[44]</xref></p>
        <p>Eribulin, a microtubule inhibitor approved for liposarcomas, has exhibited preclinical activity in SFT patient-derived xenograft models and has shown some responses in phase II trials on advanced soft tissue sarcoma. Clinical trials are currently underway to further evaluate its efficacy in SFTs.<xref ref-type="bibr" rid="article-143403.r46">[46]</xref>&#x000a0;While chemotherapy may be considered in managing advanced or metastatic SFTs, its efficacy varies among different subtypes of SFTs. Anthracycline-based regimens remain a standard approach, especially in DD-SFT, while other agents like DTIC, temozolomide, trabectedin, and eribulin show promise and are being evaluated in ongoing clinical trials. Further research and clinical data are needed to establish the optimal chemotherapy regimens and their role in managing SFTs.</p>
        <p>
<bold>Antiangiogenics</bold>
</p>
        <p>The treatment landscape for SFTs has evolved with the introduction of targeted therapies, particularly antiangiogenic agents. Here's a summary of some notable findings regarding the use of various agents in the management of SFTs:</p>
        <p><bold>Temozolomide and bevacizumab:&#x000a0;</bold>This combination therapy targeting VEGF showed promising results in a retrospective study. A high response rate (79%) was observed, with a median PFS of 9.7 months. However, the study's limitations, including a small sample size and variable radiological assessments, warrant a cautious interpretation of these findings.<xref ref-type="bibr" rid="article-143403.r47">[47]</xref></p>
        <p><bold>Sunitinib:&#x000a0;</bold>A multityrosine kinase inhibitor with activity against the VEGF receptor,platelet-derived growth factor (PDGF) receptor, and other targets, sunitinib demonstrated efficacy in a retrospective series of unfavorable SFT patients. Notably, DD-SFT cases showed less sensitivity compared to malignant SFT cases.<xref ref-type="bibr" rid="article-143403.r48">[48]</xref></p>
        <p><bold>Sorafenib:&#x000a0;</bold>Another multikinase inhibitor, sorafenib, showed activity in a small cohort of advanced and progressive SFT patients, with a median PFS of 5.9 months.<xref ref-type="bibr" rid="article-143403.r49">[49]</xref></p>
        <p><bold>Pazopanib:&#x000a0;</bold>This multitargeted receptor tyrosine kinase inhibitor exhibited activity in retrospective and prospective studies. Response rates ranged from 46% to 58%, with median PFS ranging from 4.7 to 9.8 months. The GEIS-32 trial showed favorable outcomes with pazopanib in aggressive and low-aggressive SFT cohorts.<xref ref-type="bibr" rid="article-143403.r50">[50]</xref></p>
        <p><bold>Axitinib:&#x000a0;</bold>An oral multityrosine kinase inhibitor, axitinib, demonstrated activity in a single-center trial, with a response rate of 41.2%. Notably, partial responses were observed even in patients previously treated with antiangiogenics, highlighting the potential for sequential therapy.<xref ref-type="bibr" rid="article-143403.r8">[8]</xref></p>
        <p>Antiangiogenic agents have emerged as promising therapeutic options for non-DD-SFT, showing superior activity to traditional chemotherapy. With its favorable toxicity profile and efficacy demonstrated in clinical trials, pazopanib is recommended as a first-line treatment. Sequential use of antiangiogenics and consideration of other agents like trabectedin or dacarbazine-based chemotherapy upon progression are reasonable strategies in managing SFTs. However, further research, including prospective studies and clinical trials, is needed to validate these findings and optimize treatment approaches. Patients should be encouraged to participate in ongoing clinical trials when appropriate.<xref ref-type="bibr" rid="article-143403.r6">[6]</xref></p>
      </sec>
      <sec id="article-143403.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Due to the wide range of histological patterns seen in SFTs, they have been dubbed "the great simulator" of soft tissue tumors by Machado et al.<xref ref-type="bibr" rid="article-143403.r19">[19]</xref> These tumors frequently present diagnostic challenges, requiring the incorporation of clinical, histomorphological, immunohistochemical, and molecular characteristics to diagnose them accurately. The following are some differential diagnoses to consider when evaluating a suspected SFT:</p>
        <list list-type="bullet">
          <list-item>
            <p>Gastrointestinal stroma tumor</p>
          </list-item>
          <list-item>
            <p>Leiomyosarcoma&#x000a0;<xref ref-type="bibr" rid="article-143403.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>Schwannoma</p>
          </list-item>
          <list-item>
            <p>Fibromyxoid sarcoma&#x000a0;<xref ref-type="bibr" rid="article-143403.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>Myofibroblastoma</p>
          </list-item>
          <list-item>
            <p>Angiofibroma</p>
          </list-item>
          <list-item>
            <p>Fibroblastic spindle cell tumor</p>
          </list-item>
          <list-item>
            <p>Spindle cell lipoma</p>
          </list-item>
          <list-item>
            <p>Fibroma</p>
          </list-item>
          <list-item>
            <p>Pseudoangiomatous stromal proliferation</p>
          </list-item>
          <list-item>
            <p>Synovial sarcoma&#x000a0;<xref ref-type="bibr" rid="article-143403.r26">[26]</xref></p>
          </list-item>
          <list-item>
            <p>Malignant mesothelioma</p>
          </list-item>
          <list-item>
            <p>Sarcomatoid mesothelioma&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Desmoid tumor</p>
          </list-item>
          <list-item>
            <p>Neurogenic tumors</p>
          </list-item>
          <list-item>
            <p>Lymphoma</p>
          </list-item>
          <list-item>
            <p>Soft tissue sarcoma</p>
          </list-item>
          <list-item>
            <p>Deep fibrous histiocytoma&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Dedifferentiated liposarcoma&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Malignant peripheral nerve sheath tumor&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Dermatofibrosarcoma protuberans</p>
          </list-item>
          <list-item>
            <p>Metastases&#x000a0;<xref ref-type="bibr" rid="article-143403.r3">[3]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-143403.s11" sec-type="Staging">
        <title>Staging</title>
        <p>The 2013 WHO classification of soft tissue sarcomas marked a significant advancement in differentiating various sarcomas, categorizing SFT as a fibroblastic/myofibroblastic tumor. Consequently, the staging of SFTs adheres to the general principles applied to soft tissue sarcomas. The primary staging system utilized for soft tissue sarcomas is the American Joint Committee on Cancer's TNM (primary tumor [T], lymph nodes [N], distant metastasis [M]) staging system. Nonetheless, it's crucial to acknowledge that SFTs possess unique characteristics that may not always align perfectly with conventional staging frameworks.<xref ref-type="bibr" rid="article-143403.r7">[7]</xref></p>
        <p>
<bold>TNM Staging</bold>
</p>
        <p><bold>T, Primary tumor:&#x000a0;</bold>This staging system component describes the primary tumor's size and extent. Factors such as tumor size, invasion depth, and adjacent structures' involvement are considered. SFTs can vary widely in size and may involve nearby tissues or organs, influencing their T stage.</p>
        <p><bold>N, Lymph nodes:&#x000a0;</bold>SFTs typically do not metastasize to regional lymph nodes. Lymph node involvement is rare in SFTs, so nodal staging is usually not applicable in most cases.</p>
        <p><bold>M, Distant metastasis:&#x000a0;</bold>Metastasis refers to the spread of cancer to distant sites in the body. SFTs can potentially metastasize, commonly to the lungs, liver, bones, or other soft tissues. The presence or absence of metastases determines the M stage.</p>
        <p><bold>Grade:&#x000a0;</bold>While not officially part of the TNM staging system, tumor grade is an important prognostic factor for SFTs. Based on histological features such as cellularity, mitotic rate, necrosis, and degree of differentiation, SFTs are typically classified as benign or malignant.<xref ref-type="bibr" rid="article-143403.r7">[7]</xref>&#x000a0;Malignant SFTs have a higher risk of recurrence and metastasis compared to benign tumors.</p>
        <p><bold>Risk Stratification:&#x000a0;</bold>In addition to TNM staging, risk stratification systems have been proposed for SFTs to help guide management and predict prognosis. These systems often incorporate tumor size, location, histological features, and patient characteristics to classify tumors into low-, intermediate-, or high-risk categories.</p>
        <p><bold>Clinical Presentation:&#x000a0;</bold>The clinical presentation of SFTs, including symptoms, tumor location, and patient factors, also influences the overall stage and management approach.</p>
        <p>Overall, staging SFTs involves a multidisciplinary approach, with input from pathologists, radiologists, oncologists, and surgeons to assess tumor characteristics, determine the extent of disease spread, and develop individualized treatment plans.</p>
      </sec>
      <sec id="article-143403.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>SFTs exhibit a spectrum of biological behaviors, with the majority displaying benign but potentially locally aggressive behavior, while a subset demonstrates malignant behavior. Predicting the behavior of individual SFTs is challenging, as histologically benign tumors may exhibit aggressive recurrence. Nonetheless, the overall prognosis for SFT is generally favorable compared to many adenocarcinomas, with 5-year survival rates ranging from 59% to 100% and 10-year survival rates between 40% and 89%. The tumor's location significantly influences prognosis. Tumors found outside the thoracic region, such as those in the meninges, pelvis, retroperitoneum, and mediastinum, are linked to higher recurrence risks and potentially poorer prognoses than thoracic tumors. Meningeal SFTs, in particular, often display increased cellularity and higher mitotic counts, contributing to a worse prognosis than SFTs outside the meninges.<xref ref-type="bibr" rid="article-143403.r8">[8]</xref></p>
        <p>Several factors have been associated with prognosis in SFTs. Studies have identified recurrent tumors, positive resection margins (macro or microscopically), tumor size larger than 10 cm, presence of more than 4 mitoses per 10 high-power fields, increased nuclear pleomorphism, higher cellularity, and the presence of malignant components as poor prognostic indicators. Other factors such as tumor necrosis or hemorrhage, increased cellularity, and pleomorphism have also been linked to malignant behavior and worse prognosis. Demicco et al proposed a risk stratification model based on patient age, tumor size, and mitotic figures per 10 high-powered fields&#x000a0;to classify patients into low-, intermediate-, and high-risk categories.<xref ref-type="bibr" rid="article-143403.r8">[8]</xref>&#x000a0;This model provides a framework for assessing prognosis and guiding treatment decisions in patients with SFTs. A comprehensive evaluation of these prognostic factors is essential for risk stratification and optimizing management.<xref ref-type="bibr" rid="article-143403.r7">[7]</xref></p>
      </sec>
      <sec id="article-143403.s13" sec-type="Complications">
        <title>Complications</title>
        <p>SFTs can lead to various complications depending on size, location, and aggressiveness. Some of the common complications associated with SFTs include:</p>
        <p><bold>Local invasion:&#x000a0;</bold>SFTs may infiltrate nearby tissues and organs, causing compression, displacement, or invasion. This invasion can lead to symptoms such as pain, obstruction, or dysfunction of affected structures.</p>
        <p><bold>Compression symptoms:&#x000a0;</bold>Depending on their location and size, SFTs can compress adjacent structures, nerves, or blood vessels, leading to pain, neurological deficits, or vascular compromise.</p>
        <p><bold>Hemorrhage or necrosis:&#x000a0;</bold>Larger SFTs may outgrow their blood supply, leading to hemorrhage or necrosis within the tumor, possibly causing acute symptoms such as pain, hemodynamic instability, or signs of organ dysfunction.</p>
        <p><bold>Functional impairment:&#x000a0;</bold>SFTs located in critical anatomical sites, such as the central nervous system or major blood vessels, can impair organ function or cause neurological deficits. For example, meningeal SFTs can lead to neurological symptoms due to compression of the brain or spinal cord.</p>
        <p><bold>Obstructive symptoms:&#x000a0;</bold>SFTs in the abdomen, pelvis, or retroperitoneum may obstruct the gastrointestinal tract, urinary system, or bile ducts, leading to abdominal pain, vomiting, or jaundice.</p>
        <p><bold>Paraneoplastic syndromes:&#x000a0;</bold>In rare cases, SFTs may produce hormones or cytokines that result in paraneoplastic syndromes, such as hypoglycemia (Doege-Potter syndrome) or hypertrophic osteoarthropathy (Pierre-Marie Bamberger syndrome).</p>
        <p><bold>Complications of treatment:&#x000a0;</bold>Surgical resection, radiation therapy, or systemic therapies for SFTs can also lead to complications such as wound infections, radiation dermatitis, or chemotherapy-related side effects.</p>
        <p><bold>Recurrence:&#x000a0;</bold>Despite complete surgical resection, SFTs can potentially recur locally. The risk of recurrence is higher with larger tumors, positive surgical margins, and tumors exhibiting malignant features.</p>
        <p><bold>Metastasis:&#x000a0;</bold>Malignant SFTs can metastasize to distant organs such as the lungs, liver, bone, or soft tissues. Metastatic spread may result in the development of secondary tumors at these sites, leading to additional complications and worsening prognosis.</p>
        <p><bold>Psychological impact:&#x000a0;</bold>Coping with a diagnosis of SFT, especially if malignant or recurrent, can have psychological implications for patients and their families, including anxiety, depression, or emotional distress.</p>
        <p>Overall, the complications associated with SFTs can vary widely and depend on multiple factors, including tumor characteristics, anatomical location, and individual patient factors. Early detection, comprehensive evaluation, and multidisciplinary management are essential to minimize complications and optimize outcomes for patients with SFTs.</p>
      </sec>
      <sec id="article-143403.s14" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <p>Routine follow-up is crucial for patients with SFTs following surgical resection. Oncologic surveillance allows for the early detection and treatment of recurrent (local recurrence occurs in about 8% of cases) or metastatic disease. However, due to the rarity of SFTs, there are no established guidelines for surveillance. Various research groups have attempted to develop risk models to guide postoperative surveillance, but results have been inconsistent.&#x000a0;Results from an MD Anderson Cancer Center study identified high-risk factors associated with metastasis, including tumor size greater than 15 cm, age&#x000a0;older than 55, and a high mitotic rate (more than 4 mitoses per 10&#x000a0;high-power fields). Patients with these risk factors warrant close surveillance.<xref ref-type="bibr" rid="article-143403.r7">[7]</xref></p>
        <p>Postoperative surveillance typically involves imaging the primary tumor site every 3 to 4 months for the first 2 years after surgery, followed by every 6 months for years 2 through 5. After 5 years, imaging may no longer be necessary, as local recurrence at this point is uncommon.<xref ref-type="bibr" rid="article-143403.r51">[51]</xref>&#x000a0;Surveillance protocols should be tailored to each patient based on tumor location and other clinical characteristics. Since SFTs can recur many years after initial diagnosis and treatment, lifetime surveillance may be necessary for some patients.<xref ref-type="bibr" rid="article-143403.r7">[7]</xref></p>
      </sec>
      <sec id="article-143403.s15" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Deterrence and patient education regarding SFTs play crucial roles in early detection, prompt treatment, and to prevent complications. Launching awareness campaigns to educate the general public and healthcare professionals about SFTs can help improve early detection rates. These campaigns can include information about risk factors, common symptoms, and the importance of regular check-ups.&#x000a0;</p>
        <p>Educating individuals about potential risk factors associated with SFTs, such as age, gender, and exposure to certain environmental factors, can help them recognize when they may be at higher risk and prompt them to seek medical attention if they experience concerning symptoms. Information about common symptoms of SFTs, such as the development of a palpable mass, pain, or other unexplained symptoms, can help individuals recognize when they should consult a healthcare professional for further evaluation. Emphasizing the importance of early detection and timely medical intervention can encourage individuals to seek medical attention promptly if they notice any unusual changes in their health. Early detection often leads to better treatment outcomes and can help prevent disease progression.</p>
        <p>Educating patients about the diagnostic procedures used to evaluate SFTs, such as imaging tests (eg, MRI, CT scans) and biopsy, can help alleviate concerns and ensure patients understand the purpose of these tests in confirming a diagnosis and guiding treatment decisions. Providing information about the available treatment options for SFTs, including surgical resection, radiation therapy, and chemotherapy, can empower patients to make informed decisions about their care in collaboration with their healthcare providers. Stressing the importance of regular follow-up appointments and surveillance imaging after treatment completion can help ensure that any potential recurrences or complications are detected early and promptly addressed.</p>
        <p>Connecting patients and their families with support resources, such as patient advocacy organizations and support groups, can provide valuable emotional support and practical assistance throughout their treatment journey. Encouraging patients to adopt healthy lifestyle habits, such as maintaining a balanced diet, engaging in regular physical activity, and avoiding tobacco and excessive alcohol consumption, can help promote overall well-being and potentially reduce the risk of recurrence. Informing patients about ongoing clinical trials investigating new treatment approaches for SFTs can offer them opportunities to participate in research and access cutting-edge therapies that may not be available through standard treatment options. By implementing these strategies, clinicians can empower patients with the knowledge and resources they need to take an active role in their care, promote early detection, and improve overall outcomes for individuals affected by SFTs.</p>
      </sec>
      <sec id="article-143403.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Enhancing patient-centered care and improving outcomes for individuals with solitary fibrous tumors requires a collaborative effort from physicians, advanced practitioners, nurses, pharmacists, and other health professionals. Physicians are crucial in accurately diagnosing SFTs through comprehensive clinical evaluation and appropriate diagnostic testing. They must stay updated on the latest imaging techniques and molecular marker advancements for accurate diagnosis and treatment planning. Advanced clinicians can assist in patient assessment, provide education and counseling, and facilitate communication between patients and the healthcare team. Nurses play a vital role in patient care by providing support, monitoring for potential complications, and coordinating care across various healthcare settings.</p>
        <p>Effective interprofessional communication is essential for coordinating care and ensuring seamless transitions between different phases of treatment. Regular interdisciplinary team meetings can facilitate discussion, collaboration, and shared decision-making among healthcare professionals managing SFT patients. Pharmacists contribute to patient care by ensuring appropriate medication management, monitoring potential drug interactions, and educating patients about medication adherence and possible side effects. Additionally, involving other health professionals, such as social workers and physical therapists, can address the holistic needs of patients, including psychosocial support and rehabilitation services. By working together as a cohesive team, healthcare professionals can provide comprehensive, patient-centered care to individuals with SFTs, improving patient care, safety, and overall team performance.</p>
      </sec>
      <sec id="article-143403.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=143403&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=143403">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/solitary-fibrous-tumors/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=143403">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/143403/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=143403">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-143403.s18">
        <title>References</title>
        <ref id="article-143403.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klemperer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Coleman</surname>
                <given-names>BR</given-names>
              </name>
            </person-group>
            <article-title>Primary neoplasms of the pleura. A report of five cases.</article-title>
            <source>Am J Ind Med</source>
            <year>1992</year>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-31</page-range>
            <pub-id pub-id-type="pmid">1415270</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chick</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Chauhan</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Madan</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Solitary fibrous tumors of the thorax: nomenclature, epidemiology, radiologic and pathologic findings, differential diagnoses, and management.</article-title>
            <source>AJR Am J Roentgenol</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>200</volume>
            <issue>3</issue>
            <fpage>W238</fpage>
            <page-range>W238-48</page-range>
            <pub-id pub-id-type="pmid">23436868</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tariq</surname>
                <given-names>MU</given-names>
              </name>
              <name>
                <surname>Din</surname>
                <given-names>NU</given-names>
              </name>
              <name>
                <surname>Abdul-Ghafar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>YK</given-names>
              </name>
            </person-group>
            <article-title>The many faces of solitary fibrous tumor; diversity of histological features, differential diagnosis and role of molecular studies and surrogate markers in avoiding misdiagnosis and predicting the behavior.</article-title>
            <source>Diagn Pathol</source>
            <year>2021</year>
            <month>Apr</month>
            <day>20</day>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>32</fpage>
            <pub-id pub-id-type="pmid">33879215</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Shan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ge</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Solitary fibrous tumor of the pleura: an analysis of 13 cases.</article-title>
            <source>World J Surg</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>32</volume>
            <issue>8</issue>
            <fpage>1663</fpage>
            <page-range>1663-8</page-range>
            <pub-id pub-id-type="pmid">18427887</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Pinieux</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Karanian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Le Loarer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Le Guellec</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chabaud</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Terrier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bouvier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Batistella</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Neuville</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Robin</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Emile</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Moreau</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Larousserie</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Leroux</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stock</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lae</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Collin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Weinbreck</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Aubert</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mishellany</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Charon-Barra</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Croce</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Doucet</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Quintin-Rouet</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Chateau</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Bazille</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Valo</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Chetaille</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ortonne</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Brouchet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rochaix</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Demuret</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ghnassia</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Mescam</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Macagno</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Birtwisle-Peyrottes</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Delfour</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Angot</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pommepuy</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ranchere</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chemin-Airiau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jean-Denis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fayet</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Courr&#x000e8;ges</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Mesli</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Berchoud</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Toulmonde</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Italiano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Le Cesne</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Penel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ducimetiere</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gouin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Coindre</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Blay</surname>
                <given-names>JY</given-names>
              </name>
              <collab>NetSarc/RePPS/ResSos and French Sarcoma Group- Groupe d&#x02019;Etude des Tumeurs Osseuses (GSF-GETO) networks</collab>
            </person-group>
            <article-title>Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network.</article-title>
            <source>PLoS One</source>
            <year>2021</year>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>e0246958</fpage>
            <pub-id pub-id-type="pmid">33630918</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahmed</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Blanco</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weisberg</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Fishman</surname>
                <given-names>EK</given-names>
              </name>
            </person-group>
            <article-title>CT of retroperitoneal solitary fibrous tumor.</article-title>
            <source>Radiol Case Rep</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>18</volume>
            <issue>6</issue>
            <fpage>2241</fpage>
            <page-range>2241-2244</page-range>
            <pub-id pub-id-type="pmid">37123044</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davanzo</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Emerson</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Lisy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Koniaris</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Kays</surname>
                <given-names>JK</given-names>
              </name>
            </person-group>
            <article-title>Solitary fibrous tumor.</article-title>
            <source>Transl Gastroenterol Hepatol</source>
            <year>2018</year>
            <volume>3</volume>
            <fpage>94</fpage>
            <pub-id pub-id-type="pmid">30603730</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martin-Broto</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mondaza-Hernandez</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Moura</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Hindi</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>A Comprehensive Review on Solitary Fibrous Tumor: New Insights for New Horizons.</article-title>
            <source>Cancers (Basel)</source>
            <year>2021</year>
            <month>Jun</month>
            <day>10</day>
            <volume>13</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">34200924</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boothe</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Budd</surname>
                <given-names>GT</given-names>
              </name>
              <name>
                <surname>Smolkin</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Durable Near-Complete Response to Anti-PD-1 Checkpoint Immunotherapy in a Refractory Malignant Solitary Fibrous Tumor of the Pleura.</article-title>
            <source>Case Rep Oncol</source>
            <year>2017</year>
            <season>Sep-Dec</season>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>998</fpage>
            <page-range>998-1005</page-range>
            <pub-id pub-id-type="pmid">29279705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allen</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Labella</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Sheehan</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Kersh</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Recurrent Solitary Fibrous Tumor (Intracranial Hemangiopericytoma) Treated With a Novel Combined-Modality Radiosurgery Technique: A Case Report and Review of the Literature.</article-title>
            <source>Front Oncol</source>
            <year>2022</year>
            <volume>12</volume>
            <fpage>907324</fpage>
            <pub-id pub-id-type="pmid">35720016</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tapias</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Mercier</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ghigna</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Lahon</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mathisen</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Dartevelle</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lanuti</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Validation of a scoring system to predict recurrence of resected solitary fibrous tumors of the pleura.</article-title>
            <source>Chest</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>147</volume>
            <issue>1</issue>
            <fpage>216</fpage>
            <page-range>216-223</page-range>
            <pub-id pub-id-type="pmid">25103552</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodr&#x000ed;guez</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Martino</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Mazeyra</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;n-P&#x000e9;rez</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Solitary fibrous tumor of the pancreas.</article-title>
            <source>Autops Case Rep</source>
            <year>2021</year>
            <volume>11</volume>
            <fpage>e2021245</fpage>
            <pub-id pub-id-type="pmid">34307213</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kawaguchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kinowaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tamura</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nishikawa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shibata</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ogura</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kawabata</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Solitary fibrous tumor of male breast: A case report and literature review.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2022</year>
            <month>Dec</month>
            <day>16</day>
            <volume>101</volume>
            <issue>50</issue>
            <fpage>e32199</fpage>
            <pub-id pub-id-type="pmid">36550858</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rao</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Colby</surname>
                <given-names>TV</given-names>
              </name>
              <name>
                <surname>Falconieri</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Moran</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Suster</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Intrapulmonary solitary fibrous tumors: clinicopathologic and immunohistochemical study of 24 cases.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>37</volume>
            <issue>2</issue>
            <fpage>155</fpage>
            <page-range>155-66</page-range>
            <pub-id pub-id-type="pmid">23108019</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Neill</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Tirumani</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Do</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Keraliya</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Hornick</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Shinagare</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Ramaiya</surname>
                <given-names>NH</given-names>
              </name>
            </person-group>
            <article-title>Metastatic Patterns of Solitary Fibrous Tumors: A Single-Institution Experience.</article-title>
            <source>AJR Am J Roentgenol</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>208</volume>
            <issue>1</issue>
            <fpage>2</fpage>
            <page-range>2-9</page-range>
            <pub-id pub-id-type="pmid">27762594</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meng</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Solitary fibrous tumors of the pleura with Doege-Potter syndrome: a case report and three-decade review of the literature.</article-title>
            <source>BMC Res Notes</source>
            <year>2014</year>
            <month>Aug</month>
            <day>11</day>
            <volume>7</volume>
            <fpage>515</fpage>
            <pub-id pub-id-type="pmid">25113505</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferretti</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Chiles</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cox</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Choplin</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Coulomb</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Localized benign fibrous tumors of the pleura: MR appearance.</article-title>
            <source>J Comput Assist Tomogr</source>
            <year>1997</year>
            <season>Jan-Feb</season>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>115</fpage>
            <page-range>115-20</page-range>
            <pub-id pub-id-type="pmid">9022782</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koliakos</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chappalley</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kalogiannis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sgardello</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Christodoulou</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pierre-Marie Bamberger Syndrome Leading to the Diagnosis and Surgical Treatment of a Localized Lung Cancer.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Nov</month>
            <volume>15</volume>
            <issue>11</issue>
            <fpage>e48991</fpage>
            <pub-id pub-id-type="pmid">38111395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Machado</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Nieto-Morales</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cruz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Navarro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Giner</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ferrandez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Soto</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Lavernia</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Llombart-Bosch</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Controversial issues in soft tissue solitary fibrous tumors: A pathological and molecular review.</article-title>
            <source>Pathol Int</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>70</volume>
            <issue>3</issue>
            <fpage>129</fpage>
            <page-range>129-139</page-range>
            <pub-id pub-id-type="pmid">31904167</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cardillo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Facciolo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cavazzana</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Capece</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gasparri</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Martelli</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Localized (solitary) fibrous tumors of the pleura: an analysis of 55 patients.</article-title>
            <source>Ann Thorac Surg</source>
            <year>2000</year>
            <month>Dec</month>
            <volume>70</volume>
            <issue>6</issue>
            <fpage>1808</fpage>
            <page-range>1808-12</page-range>
            <pub-id pub-id-type="pmid">11156076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Perrot</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Br&#x000fc;ndler</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Sekine</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Keshavjee</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Solitary fibrous tumors of the pleura.</article-title>
            <source>Ann Thorac Surg</source>
            <year>2002</year>
            <month>Jul</month>
            <volume>74</volume>
            <issue>1</issue>
            <fpage>285</fpage>
            <page-range>285-93</page-range>
            <pub-id pub-id-type="pmid">12118790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sardaro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mammucci</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Piscitelli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rubini</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Maggialetti</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>The significant role of multimodality imaging with <sup>18</sup>Fluorocholine PET/CT in relapsed intracranial hemangiopericytoma.</article-title>
            <source>Rev Esp Med Nucl Imagen Mol (Engl Ed)</source>
            <year>2022</year>
            <season>Sep-Oct</season>
            <volume>41</volume>
            <issue>5</issue>
            <fpage>329</fpage>
            <page-range>329-331</page-range>
            <pub-id pub-id-type="pmid">36100316</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Han</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Immunohistochemical detection of STAT6, CD34, CD99 and BCL-2 for diagnosing solitary fibrous tumors/hemangiopericytomas.</article-title>
            <source>Int J Clin Exp Pathol</source>
            <year>2015</year>
            <volume>8</volume>
            <issue>10</issue>
            <fpage>13166</fpage>
            <page-range>13166-75</page-range>
            <pub-id pub-id-type="pmid">26722515</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sardaro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mammucci</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pisani</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Rubini</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nappi</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Bardoscia</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rubini</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Intracranial Solitary Fibrous Tumor: A "New" Challenge for PET Radiopharmaceuticals.</article-title>
            <source>J Clin Med</source>
            <year>2022</year>
            <month>Aug</month>
            <day>14</day>
            <volume>11</volume>
            <issue>16</issue>
            <pub-id pub-id-type="pmid">36012988</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Solitary fibrous tumor of the mesentery: a case report and review of the literature.</article-title>
            <source>J Int Med Res</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>48</volume>
            <issue>10</issue>
            <fpage>300060520950111</fpage>
            <pub-id pub-id-type="pmid">33050750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Perrot</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kurt</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Robert</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Borisch</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Spiliopoulos</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Clinical behavior of solitary fibrous tumors of the pleura.</article-title>
            <source>Ann Thorac Surg</source>
            <year>1999</year>
            <month>May</month>
            <volume>67</volume>
            <issue>5</issue>
            <fpage>1456</fpage>
            <page-range>1456-9</page-range>
            <pub-id pub-id-type="pmid">10355431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sureka</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Thukral</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>Mittal</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Mittal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sinha</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Radiological review of pleural tumors.</article-title>
            <source>Indian J Radiol Imaging</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>313</fpage>
            <page-range>313-20</page-range>
            <pub-id pub-id-type="pmid">24604935</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Im</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Choe</surname>
                <given-names>KO</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>BH</given-names>
              </name>
            </person-group>
            <article-title>CT findings in benign fibrous mesothelioma of the pleura: pathologic correlation in nine patients.</article-title>
            <source>AJR Am J Roentgenol</source>
            <year>1992</year>
            <month>May</month>
            <volume>158</volume>
            <issue>5</issue>
            <fpage>983</fpage>
            <page-range>983-6</page-range>
            <pub-id pub-id-type="pmid">1566702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cardillo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lococo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Carleo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Martelli</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Solitary fibrous tumors of the pleura.</article-title>
            <source>Curr Opin Pulm Med</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>339</fpage>
            <page-range>339-46</page-range>
            <pub-id pub-id-type="pmid">22450304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Desser</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Stark</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Pictorial essay: solitary fibrous tumor of the pleura.</article-title>
            <source>J Thorac Imaging</source>
            <year>1998</year>
            <month>Jan</month>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>27</fpage>
            <page-range>27-35</page-range>
            <pub-id pub-id-type="pmid">9440836</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saifuddin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Da Costa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chalmers</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Robertson</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Primary malignant localized fibrous tumours of the pleura: clinical, radiological and pathological features.</article-title>
            <source>Clin Radiol</source>
            <year>1992</year>
            <month>Jan</month>
            <volume>45</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-7</page-range>
            <pub-id pub-id-type="pmid">1740027</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shanahan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Redmond</surname>
                <given-names>KC</given-names>
              </name>
            </person-group>
            <article-title>Largest known malignant solitary fibrous tumour of the pleura-extended resection warranting cardiopulmonary bypass support.</article-title>
            <source>Ir J Med Sci</source>
            <year>2019</year>
            <month>May</month>
            <volume>188</volume>
            <issue>2</issue>
            <fpage>433</fpage>
            <page-range>433-435</page-range>
            <pub-id pub-id-type="pmid">30058053</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ginat</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Bokhari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dogra</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Imaging features of solitary fibrous tumors.</article-title>
            <source>AJR Am J Roentgenol</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>196</volume>
            <issue>3</issue>
            <fpage>487</fpage>
            <page-range>487-95</page-range>
            <pub-id pub-id-type="pmid">21343490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tazeler</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Aslan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The utility of 18F-FDG PET/CT in solitary fibrous tumors of the pleura.</article-title>
            <source>Rev Esp Med Nucl Imagen Mol</source>
            <year>2016</year>
            <season>May-Jun</season>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>165</fpage>
            <page-range>165-70</page-range>
            <pub-id pub-id-type="pmid">26632105</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jain</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Pandey</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Saini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patne</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Large Solitary Fibrous Tumor (SFT) of the penis- a case report and review of literature.</article-title>
            <source>BMC Urol</source>
            <year>2023</year>
            <month>Aug</month>
            <day>02</day>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>131</fpage>
            <pub-id pub-id-type="pmid">37533000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ali</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Aftab</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Akram</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Solitary Fibrous Tumors of the Pleura.</article-title>
            <source>Cureus</source>
            <year>2021</year>
            <month>Jan</month>
            <day>30</day>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>e12998</fpage>
            <pub-id pub-id-type="pmid">33659132</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lahon</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mercier</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Fadel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ghigna</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Petkova</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mussot</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fabre</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Le Chevalier</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dartevelle</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Solitary fibrous tumor of the pleura: outcomes of 157 complete resections in a single center.</article-title>
            <source>Ann Thorac Surg</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>94</volume>
            <issue>2</issue>
            <fpage>394</fpage>
            <page-range>394-400</page-range>
            <pub-id pub-id-type="pmid">22704328</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Shao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Thoracic solitary fibrous tumors: an analysis of 70 patients who underwent surgical resection in a single institution.</article-title>
            <source>J Cancer Res Clin Oncol</source>
            <year>2020</year>
            <month>May</month>
            <volume>146</volume>
            <issue>5</issue>
            <fpage>1245</fpage>
            <page-range>1245-1252</page-range>
            <pub-id pub-id-type="pmid">32056008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aridi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tawil</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hashem</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khoury</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Raad</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Youssef</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Unique Presentation and Management Approach of Pleural Solitary Fibrous Tumor.</article-title>
            <source>Case Rep Surg</source>
            <year>2019</year>
            <volume>2019</volume>
            <fpage>9706825</fpage>
            <pub-id pub-id-type="pmid">31886010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Surgical treatment of primary solitary fibrous tumors involving the pelvic ring.</article-title>
            <source>PLoS One</source>
            <year>2018</year>
            <volume>13</volume>
            <issue>11</issue>
            <fpage>e0207581</fpage>
            <pub-id pub-id-type="pmid">30481195</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Macagno</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Vogels</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Appay</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Colin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mokhtari</surname>
                <given-names>K</given-names>
              </name>
              <collab>French CNS SFT/HPC Consortium</collab>
              <collab>Dutch CNS SFT/HPC Consortium</collab>
              <name>
                <surname>K&#x000fc;sters</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wesseling</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Figarella-Branger</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Flucke</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Bouvier</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Grading of meningeal solitary fibrous tumors/hemangiopericytomas: analysis of the prognostic value of the Marseille Grading System in a cohort of 132 patients.</article-title>
            <source>Brain Pathol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>18</fpage>
            <page-range>18-27</page-range>
            <pub-id pub-id-type="pmid">29600523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haas</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Walraven</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lecointe-Artzner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>van Houdt</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Scholten</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Strauss</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schrage</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hayes</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Raut</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Fairweather</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baldini</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Gronchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De Rosa</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Wunder</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>van de Sande</surname>
                <given-names>MAJ</given-names>
              </name>
              <name>
                <surname>Krol</surname>
                <given-names>ADG</given-names>
              </name>
              <name>
                <surname>Skoczylas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brandsma</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Doglietto</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sangalli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stacchiotti</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Management of meningeal solitary fibrous tumors/hemangiopericytoma; surgery alone or surgery plus postoperative radiotherapy?</article-title>
            <source>Acta Oncol</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>60</volume>
            <issue>1</issue>
            <fpage>35</fpage>
            <page-range>35-41</page-range>
            <pub-id pub-id-type="pmid">32988268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haas</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Walraven</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lecointe-Artzner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Scholten</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>van Houdt</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Miah</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Zaidi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>DeLaney</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Spalek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Krol</surname>
                <given-names>SDG</given-names>
              </name>
              <name>
                <surname>Moeri-Schimmel</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>van de Sande</surname>
                <given-names>MAJ</given-names>
              </name>
              <name>
                <surname>Sangalli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stacchiotti</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Radiation Therapy as Sole Management for Solitary Fibrous Tumors (SFT): A Retrospective Study From the Global SFT Initiative in Collaboration With the Sarcoma Patients EuroNet.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2018</year>
            <month>Aug</month>
            <day>01</day>
            <volume>101</volume>
            <issue>5</issue>
            <fpage>1226</fpage>
            <page-range>1226-1233</page-range>
            <pub-id pub-id-type="pmid">29859795</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stacchiotti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Saponara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Frapolli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tortoreto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cominetti</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Provenzano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Negri</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dagrada</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Gronchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Colombo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vincenzi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Badalamenti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zuco</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Renne</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Collini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Morosi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Dei Tos</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Bello</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pilotti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Casali</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>D'Incalci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zaffaroni</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.</article-title>
            <source>Eur J Cancer</source>
            <year>2017</year>
            <month>May</month>
            <volume>76</volume>
            <fpage>84</fpage>
            <page-range>84-92</page-range>
            <pub-id pub-id-type="pmid">28284173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stacchiotti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tortoreto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bozzi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tamborini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Morosi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Messina</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Libertini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Palassini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cominetti</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Negri</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gronchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pilotti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zaffaroni</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Casali</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <article-title>Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics.</article-title>
            <source>Clin Cancer Res</source>
            <year>2013</year>
            <month>Sep</month>
            <day>15</day>
            <volume>19</volume>
            <issue>18</issue>
            <fpage>5192</fpage>
            <page-range>5192-201</page-range>
            <pub-id pub-id-type="pmid">23888069</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kawai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Araki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Naito</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ozaki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sugiura</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yazawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Morioka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Matsumine</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Asami</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Isu</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma.</article-title>
            <source>Jpn J Clin Oncol</source>
            <year>2017</year>
            <month>Feb</month>
            <day>01</day>
            <volume>47</volume>
            <issue>2</issue>
            <fpage>137</fpage>
            <page-range>137-144</page-range>
            <pub-id pub-id-type="pmid">28173193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Ludwig</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Trent</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Conrad</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Lazar</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Boonsirikamchai</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Araujo</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor.</article-title>
            <source>Cancer</source>
            <year>2011</year>
            <month>Nov</month>
            <day>01</day>
            <volume>117</volume>
            <issue>21</issue>
            <fpage>4939</fpage>
            <page-range>4939-47</page-range>
            <pub-id pub-id-type="pmid">21480200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stacchiotti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Negri</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Libertini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Palassini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Marrari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De Troia</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gronchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dei Tos</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Morosi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Messina</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pilotti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Casali</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <article-title>Sunitinib malate in solitary fibrous tumor (SFT).</article-title>
            <source>Ann Oncol</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>23</volume>
            <issue>12</issue>
            <fpage>3171</fpage>
            <page-range>3171-3179</page-range>
            <pub-id pub-id-type="pmid">22711763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valentin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fournier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Penel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bompas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chaigneau</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Isambert</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chevreau</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO).</article-title>
            <source>Invest New Drugs</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>31</volume>
            <issue>6</issue>
            <fpage>1626</fpage>
            <page-range>1626-7</page-range>
            <pub-id pub-id-type="pmid">24005614</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martin-Broto</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cruz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Penel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Le Cesne</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hindi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Luna</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Moura</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Bernabeu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>de Alava</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lopez-Guerrero</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Dopazo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pe&#x000f1;a-Chilet</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gutierrez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Collini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Karanian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Redondo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lopez-Pousa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grignani</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Diaz-Martin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Marcilla</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fernandez-Serra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gonzalez-Aguilera</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Casali</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Blay</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Stacchiotti</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>456</fpage>
            <page-range>456-466</page-range>
            <pub-id pub-id-type="pmid">32066540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-143403.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abraham</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Balaji</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Verola</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Malignant Extrapleural Solitary Fibrous Tumor.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>Aug</month>
            <volume>15</volume>
            <issue>8</issue>
            <fpage>e43750</fpage>
            <pub-id pub-id-type="pmid">37605717</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
